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SUBCELLULAR LOCALIZATION OF NEDD9 AND HMB45 WITH AQUA 
TECHNOLOGY TO DISTINGUISH SPITZ NEVI FROM MELANOMA. 
Matthew C. McRae, Rossitza Lasova, Bonnie Gould-Rothberg, David Rimm (Sponsored 
by Deepak Narayan). Section of Plastic Surgery, Department of Surgery, Yale University 
School of Medicine, New Haven, CT.  
Our hypothesis is that the expression level and subcellular localization of HMB45 and 
NEDD9 as demonstrated by the ln(nuclear/non-nuclear) Automated Quantitative 
Analysis (AQUA) score, defined as the subcellular AQUA ratio, will be consistently 
altered between benign nevi and melanoma and between Spitz nevi and Spitzoid 
melanoma. Our specific aims are to assess quantitative expression and subcellular 
localization of HMB45 and NEDD9 to aid in the diagnosis of benign Spitz nevi and 
malignant Spitzoid melanoma. This remains a vexing clinical problem with important 
implications for treatment and patient care. The quantitative expression and subcellular 
AQUA ratio will be assessed in the following samples: benign derived versus malignant 
derived cell lines, human benign nevi, human primary melanoma, human metastatic 
melanoma, typical Spitz nevi, atypical Spitz nevi and Spitzoid melanoma. AQUA was 
used to quantify protein expression levels in subcellular compartments using 
fluorescence-based immunohistochemistry. Tissue Microarrays (TMA) analysis was used 
for cell line, benign nevi and malignant melanoma while whole section analysis was used 
for Spitz nevi and Spitzoid melanoma. NEDD9 subcellular AQUA ratio was significantly 




-0.429, std dev=0.108) on YTMA98-2 (p=0.0086), significantly reduced in melanoma 
metastases (mean=-0.482, std dev=0.149) versus benign nevi (mean= -0.342, std 
dev=0.159) on YTMA66A (p<0.0001), and significantly reduced in primary melanoma 
(mean= -0.435, std. dev.=0.185) and melanoma metastases (mean= -0.42, std. dev.= 
0.188) versus benign nevi (mean= -0.319, std. dev.= 0.141) in SPORE84 array 
(p=0.0003, Tukey/Kramer post-hoc significance p<0.05). HMB45 subcellular AQUA 
ratio was significantly reduced in primary melanoma (mean=-0.463, std. dev.=0.264) 
versus benign nevi (mean=-0.159, std. dev.=0.158) on YTMA 98-2 array (p=0.0001). On 
whole section analysis, the HMB45 and NEDD9 subcellular AQUA ratio shared a similar 
distribution between Spitz nevi, atypical Spitz nevi and Spitzoid melanoma. Subcellular 
localization using the subcellular AQUA ratio of HMB45 and NEDD9 defines benign 
nevi from melanoma on TMA but is not useful in discriminating between benign Spitz 
nevi and melanoma with Spitzoid features. The maximum HMB45 AQUA score in the 
tumor mask in a single 20X high-powered field of a whole tissue section was deemed 
promising on discovery analysis at differentiating between Spitz nevi and melanoma with 
Spitzoid features (p=0.007, receiver operating characteristic area under curve 0.711) but 
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Melanocytes, Nevi and Melanoma 
Melanocytes are derived from the neural crest in embryogenesis and migrate 
throughout the body to the eye, ear, leptomeninges and particularly to the basal layer of 
the epidermis. The lowest concentration of melanocytes in the epidermal basal layer is 
found in the skin of the trunk and upper arm with 800 to1000 per square millimeter 
(roughly one melanocyte per ten keratinocytes) while the highest concentration is found 
on the face and genitalia with over 2000 melanocytes present per millimeter of skin 
(roughly one melanocyte per four keratinocytes)1. The total melanocyte mass in the body 
is thought to range between 1 and 1.5 mL2. The difference in skin tone between human 
beings is a result of the basal activity level of melanocytes instead of relative number of 
cells as the relative concentration of melanocytes is independent of race and sex 3.  
Melanocytes transfer melanosomes to surrounding keratinocytes to protect their 
nuclei from ultra-violet radiation. Freckles or lentigo result from isolated clusters of 
heavily pigmented keratinocytes. In contrast, acquired nevi are a benign neoplasm or 
hamartoma of melanocytes that have overcome contact inhibition to form nests of cells in 
response to inciting factor such as UV light4. If present at birth, nevi are congenital and 
are thought to be a result of an error in development and migration of neural crest 




Congenital nevi occur in 1-3% of the population. From birth, there is an 
increasing number of acquired nevi that peak in late adolescence6. The majority of fair 
skinned individuals have several nevi. Nevi can be defined by their location in the cutis. 
Nevi are junctional if located at the border of the dermis and epidermis, intradermal if 
located entirely in the dermis and compound if located both in the dermis and epidermis.  
Nevi are recognized as a benign neoplasm with little to no chance of progression 
to malignancy. A group of researchers at Massachusetts General Hospital quantified the 
lifetime risk by age 80 of malignant transformation of any nevi greater than 3mm into 
cutaneous melanoma as 0.03% for men and 0.009% for women7. Certain variants of nevi 
are thought to have greater malignant potential over the course of a lifetime necessitating 
removal or close observation. Dysplastic nevi when associated with dysplastic nevi 
syndrome are at a greater risk of malignant transformation. Large (1-3cm) or giant 
(>3cm) congenital nevi have a lifetime incidence of malignant transformation of around 
5% although literature reviews report the incidence as being somewhere between 0 and 
42%8. 
Melanoma is the malignant transformation of melanocytes causing cancer. 
Although melanoma is the leading cause of skin cancer-related deaths worldwide, it 
accounts for only 4% of all skin cancers. The American Cancer Association estimates 
that 62,480 new melanomas were diagnosed in 2008 with 8420 deaths resulting from the 
disease. For Caucasians, 1 in 50 will get melanoma for a lifetime incidence of 2%. 
Hispanics and Blacks have far lower lifetime risk of 0.5% and 0.1 % respectively. Risk 
factors for acquiring melanoma include exposure to UV light resulting in severe burns, 




immunosupression, fair skin and xeroderma pigmentosum. Men have a slightly higher 
incidence of melanoma with higher melanoma related mortality9. 
 
Spitz Nevi 
Sophie Spitz reported on a series of childhood melanocyte lesions with 
histological features of melanoma that behaved in a benign manner10. She reported on a 
juvenile variant of cutaneous melanoma composed of spindle or epithelioid melanocytes 
in which the prognosis was excellent. Subsequent studies revealed “Spitz” nevi as benign. 
Classic and atypical Spitz nevi are an uncommonly occurring lesion of melanocytes with 
an incidence of 7 in 100,00011. They generally appear in the head and neck region or the 
lower extremities of a child as a pink papule but they can also be heavily pigmented. 
They derive either from pre-existent nevi or arise de novo and rapidly grow to a size of 
around 1cm at which point they often become quiescent. Incomplete removal can result 
in recurrence. 
Spitz nevi most commonly present in children and adolescents but may also occur 
in adults. 50% occur by age 10 and 70% occur by age 20. A study completed at Yale 
University reported on the incidence of Spitz Nevi according to age and showed that the 
ratio of Spitz Nevi to melanoma varies with age. In those younger than 20 years of age 
the ratio of Spitz nevi to melanoma is 60 to 1. In people over age 50, the ratio of Spitz 
nevi to melanoma is 1 to 60.12 
Despite greater than 60 years of study, there remains no consensus among 




reliant on more than just the clinical history and macroscopic appearance of the lesion. 
Commonly found pathologic features of Spitz nevi fall into major and minor histological 
criteria and are summarized below: 
Table 1: Criteria Used for Establishing Diagnosis of Spitz Nevi. Adapted from Crotty et 
al. and Dahlstrom et al13, 14. 
Major Criteria Minor Criteria 
 
Symmetry and well circumscribed lateral 
margins. Lack of lateral extension of 
junctional nevus cells beyond dermal nevus 
cells. 
 
Epithelioid and/or spindle cells. Spindle 
cells are more common. Cells arranged in 
fascicles with vertical orientation related to 
the rete ridges. 
 
Maturation of the deep dermal component 
of the nevus. This means that nevus cells in 
the deeper part of the lesion are smaller and 
become dispersed among reticular dermal 
fibers with progressive descent into the 
dermis. 
 
Kamino Bodies, which are eosinophilic 
globules. 
 
Pagetoid (or upward) spread that is only 






Absence of nuclear pleomorphism 
 
Superficial Multinucleated Giant Cells 
 
Hyperkeratosis and acanthosis of the 
epidermis 
 
No deep or atypical mitosis (mitosis may 
be present in the junctional or superficial 
dermal components) 
 
Superficial edema, telangiectasia, 
perivascular inflammation 
NB: Most Spitz nevi do not display all of these characteristics 
 
Atypical Spitz nevi display features that are not sufficient for a diagnosis of 
melanoma. However, neither the number nor degree of atypical features for a diagnosis 




Spitz in an adult will be classified as classic Spitz in a child. Atypical features that 
classify Spitz nevi as low or high risk are listed below: 
Table 2: Atypical features of Spitz Nevi useful in classifying as low or high risk of 
malignancy.  Adapted from Barnhill et al15. 
Low Risk High Risk 
<10 years old 
No ulceration 





Minimal or low grade cytological atypia 
Few or no mitoses 
Superficial mitoses only 
Typical mitoses 
>10 years old 
Ulceration 
Large size (>10 mm) 
Asymmetry 
Deep extension (into sub cutis) 
Hypercellularity 
No maturation 
Prominent cytological atypia 




For between 80 and 90% of Spitz lesions, the diagnosis is clear11. However for the 
remaining lesions, there are clinical and histological features of melanoma. Spitzoid 
melanoma is the variant of melanoma that shares clinical features with Spitz nevi. There 
is no single discriminating factor between Spitz nevi and malignant melanoma as every 




distinguish benign Spitz nevi from melanoma with Spitzoid features are delineated 
below: 
 
Table 3: Features in Favor of Spitz nevi versus Spitzoid Melanoma. Adapted from Crotty 
et al.14 
Features of Spitz Nevi Features of Spitzoid Melanoma 
Kamino Bodies 
Symmetry 
Uniformity of nests across lesion 
Dermal mitotic rate >2/mm2 
Mitosis within 0.25 mm of the tumor base 
Atypical mitoses 
 
While Spitz nevi most commonly occur in children - a population where 
melanoma is quite rare - it is estimated that 40% of children who do develop melanoma 
are originally misdiagnosed16,17. As melanoma is on the differential of every Spitz nevus, 
differentiating between the two is incredibly important in terms of treatment (Figure1).  
 
Figure 1: H+E slides of i) typical Spitz Nevi ii) atypical Spitz Nevi and iii) Spitzoid Melanoma. 
Differentiating between these tumor types can be a challenge and while typical and atypical Spitz are 





The treatment of Spitz nevi consists of surgical excision with margins of 0.5cm. If 
the lesion is deemed melanoma, surgical margins of up to 2 cm will be necessary as well 
as sentinel node biopsy and the potential for additional immune therapy. Since Spitz nevi 
tend to occur in the head and neck region of young children, treatment of Spitz nevi as a 
melanoma can result in unnecessary morbidity from removal of larger margins of healthy 
tissue while under-treatment of melanoma can result in premature death. There are also 
medico-legal consequences of this difficult diagnosis for pathologists. A study 
investigating all malpractice claims in Napa Valley between 1998 and 2003 found that a 
false negative melanoma diagnosis was the single most common reason for malpractice 
claims against a pathologist and nearly one third of these claims involved misdiagnosis as 
Spitz nevi, dysplastic nevi, spindle-cell, squamous cell, atypical fibroxanthoma, and 
dermatofibroma18. 
 
Molecular Pathology Part1: HMB45 
Human Melanoma Black-45 (HMB-45) is a monoclonal antibody that recognizes 
the glycosylated form of gp100 protein19. Gp100 or Pmel17 is the human homolog of the 
mouse silver protein. It is required for the proper formation of melanosomal fibrils, which 
facilitates the maturation of stage I premalanosomes to stage II and is restricted to the 
fibrillar matrix of stage II premelanosomes20, 21. 
HMB45 is used for the identification of melanoma cells in sentinel lymph nodes. 




exception of desmoplastic and spindle cell types22. Junctional nevi and the epidermal 
component of compound nevi generally stain positively for HMB45 while the dermal 
component of compound nevi usually stain negatively. The HMB45 antibody in 
dysplastic nevi has been shown to stain positively in both the epidermal and dermal 
components 23. In a study that compared the HMB45 staining pattern of typical Spitz 
nevi, compound nevi and melanoma, it was shown that while 100% of the 12 melanoma 
had both epidermal and dermal staining to the base of the lesion, only 2 of 17 Spitz nevi 
and 0 of 20 compound nevi had similar staining24. 
The nuclear localization of gp100 was not appreciated until recently due to the 
limits of chromogenic staining and presence of the overwhelming hematoxylin counter-
stain on the nucleus. Gould-Rothberg et al. demonstrated that fluorescence based 
immunohistochemistry signaling enabled the discovery of differential subcellular staining 
patterns between benign nevi and malignant cells with notable HMB-45 staining in the 
nucleus of benign nevi. The ln(nuclear/non nuclear) AQUA ratio of HMB45 staining 
maximized the contrast of predominantly nuclear staining benign in nevi versus the 
predominantly cytoplasmic staining in malignant melanoma lesions with an odds ratio of 
2.24. While the cases were selected from several institutions as classic examples of the 
histotype, a maximized sensitivity of 0.92 and specificity of 0.80 suggests the potential 
utility of this ratio as a diagnostic tool in the characterization of melanocytic lesions20. 
The subcellular localization and AQUA ratio of gp100 as revealed by HMB45 
fluorescent immunostaining has yet to be characterized in Spitz nevi, representing a 





Molecular Pathology Part2: NEDD9 
 Neural precursor cell Expressed Developmentally regulated expression pattern in 
brain 9 (NEDD9) was identified in 2006 as a melanoma metastasis gene by comparative 
oncogenomics. The gene was localized to chromosome 13A3.3 in mice with the 
corresponding human homologue at 6p25-24. A group from Harvard demonstrated over 
expression of Nedd9 in metastatic melanoma relative to primary melanoma. They showed 
Nedd9 as having a role in focal adhesion contacts in the cell periphery suggesting a 
mechanism of metastasis and invasion, as well as showing enhanced invasion in vitro and 
metastasis in vivo of both normal and transformed melanocytes. The staining pattern on 
formalin fixed, paraffin embedded tissue was described as “patchy” in nevi (n=31), 
versus “strong broad over expression” in primary and metastatic melanoma (n=40), 
correlating with melanoma progression. Scores were calculated on a 0 to 4 categorical 
scale and arrived at by consensus evaluation by pathologists25. 
It has been recently shown that mesenchymal type movement of melanoma cells 
are driven by a GTPase. This GTPase is activated through a complex containing Nedd9 
26.  Nedd9 has also been implicated in glioblastoma multiforme invasion26, and is up 
regulated in lung cancer metastasis 27. 
Preliminary data in the Rimm laboratory suggest that Nedd9 shares the propensity 
for nuclear expression in the benign nevi while cytoplasmic/membranous expression 





Tissue Microarrays and Automated Quantitative Analysis 
 Tissue microarrays (TMA) permit the analysis of large cohorts of patients 
simultaneously, thus providing a high throughput method of analyzing both the 
prognostic and diagnostic utility of protein targets 28. Although several protein 
biomarkers may be targeted in a single experiment, TMAs are generally used for the 
analysis of a single target of interest but in a high throughput fashion. Putting samples on 
the same slide and staining under identical experimental conditions permit a reproducible 
method of analyzing molecular protein expression. The assay used to detect antigens in 
tissue with fluorescence-linked antibodies is known as immunohistochemistry (IHC). 
TMAs may be used for other experimental platforms as well including DNA alterations 
with fluorescence in situ hybridization and mRNA expression by in situ hybridization. 
 Automated subcellular localization and quantification of protein expression in 
tissue microarrays or AQUA(HistoRX, New Haven, CT) is image analysis software 
that permits the rapid, automated, continuous and quantitative analysis of tissue 
microarrays and tissue whole section including the subcellular localization of signal and 
separation of tumor from stroma29. Continuous, quantitative scoring is not possible with 
chromogen based IHC protocols that requires a pathologist to rely on the subjective 
discernment of the naked eye. Many conditions can influence their judgment of intensity 
of staining including background staining, stromal staining and even the order in which 
the slide is observed 28. AQUA results in scores that are directly proportional to protein 
molecules per cell. This is accomplished by incorporation of standard curves resulting 
from cell lines present within TMA cores and can therefore serve as a mechanism of 






The expression level and subcellular localization of HMB45 and NEDD9 as 
defined by ln(nuclear/non-nuclear) AQUA score have been show to be consistently 
altered between benign nevi and melanoma. Here we hypothesize that this test could be 
useful in discriminating between benign Spitz nevi and Spitzoid melanoma. 
 
Specific Aims of Thesis 
 
Aim 1 
Assess expression levels and subcellular localization of HMB45 and NEDD9 in 
benign derived versus malignant derived cell lines to validate antibodies. 
Aim 2 
Assess quantitative expression levels and subcellular AQUA ratio of HMB45 and 
NEDD9 in human benign nevi, human primary melanoma and human metastatic 
melanoma. 
Aim 3 
Assess quantitative expression levels and subcellular AQUA ratio of HMB45 and 
NEDD9 in typical Spitz nevi, atypical Spitz nevi and Spitzoid melanoma in order to 






Melanoma Tissue Microarray: 
 (Lori Charette of the Yale tissue microarray facility completed TMA preparation. 
The SPORE 84 array was provided by a peer institution). TMAs were constructed using 
the standard method 30. After tumor was removed from the patient, it was fixed in 
formalin, embedded in paraffin and archived. Tumor types were searched for and 
retrieved to form the cohort. 600-micron diameter cores from representative sections of 
tumor were then taken using a precision arraying instrument (Beecher Instruments, Silver 
Spring, MD) to form a “master block.” The cores were spaced 800 microns apart in the 
master block (600 or more tissue cores can be placed in a single master block that can 
then be sectioned to produce between 100 and 200 slides for simultaneous cohort 
analysis). Often cell line controls were placed on the tissue microarray for both internal 
and external validation of experimental procedure. Cell line pellets were made after 
growing cell lines to confluence. This was followed by 10% formalin fixation and 
embedding in paraffin. 0.6 mm cores were then made for inclusion in the master block 
and subsequently sectioned.  
 Using an ultraviolet light cross-linking transfer system the 5-micrometer thick 
sections were fastened to the adhesive slide (Instrumedics Inc., Hackensack, NJ) and 
dipped in paraffin for storage. Every 10th slide was stained with hematoxylin and eosin 
(H&E) and reviewed by a pathologist to confirm the diagnosis. During staining, an 




cut for immediate use. If slides were not used immediately, they were place in a nitrogen 
desiccation chamber to prevent antigen oxidation and breakdown. 
 For our study, we used four different tissue micro-arrays: the Yale melanoma test 
arrays, the Yale Boutique tissue microarray 98-2, the Yale Nevi Array 66A, and the 
Specialized Program Of Research Excellence (SPORE) Melanoma Progression Array 84.  
 Yale melanoma test array: A variety of test arrays were used for titering of 
antibodies to achieve ideal dilutions, and for negative control during experiments (a 
negative control is when no primary target antibody is placed on the TMA during an 
experiment). Yale Tissue Microarray (YTMA) 112 has 10 melanoma metastases, 10 
primary melanomas, 10 nevi, 6 normal skin and 4 cell lines. YTMA 109 has 10 
melanoma metastases, 10 primary melanomas, 5 benign nevi, and 5 normal skin spots. 
 Yale Boutique TMA 98-2: This TMA was constructed out of formalin-fixed, 
paraffin embedded archived material by the Yale tissue microarray facility. The cohort 
includes 20 benign nevi, 20 vertical growth phase primary melanomas, and 20 metastases 
from subcutaneous, lymph node and visceral sites. Cell lines were included in duplicate 
on the array for a total of 90 cell line spots. The 24 melanoma cell lines present were 928, 
mel888, mm127, 501, BHP 18-21, yusac2, yumor, mel624, sk23, Aaron1, 1335, yumac, 
yugen8, 1241, mnt1, yusit1, yuheikp16, yurifp5, yuficp8, yulacp8, ww165, malme314, 
skmel, skmel28. The 21 non-melanoma cells included were IMR32, CHP212, ACL-a, 
SW480, HT29, CACO2, SKOV3, A431, MB231, T47D, MB435, ZR751-B, SKBR-3-A, 
MCF7, A549, NCI-H28, H1666, H1819, H2126, H2882, ANH1299.  




constructed this TMA out of formalin-fixed, paraffin-embedded archived material. The 
cohort included 299 benign nevi, 40 melanoma metastases, 13 normal skin, and 28 spots 
for 14 melanoma cell lines allowing for a two fold redundant internal control. These 
melanoma cell lines are YUSAC2, YUMOR, MEL624, SK23, 928, MEL888, 501, 
YUSIT, MNT1, 1241, YUGEN8, AARON, 1335. 
 SPORE Melanoma Progression Array 84: This TMA was constructed from 
archived formalin-fixed, paraffin embedded tissue from MD Anderson Cancer center, the 
University of Pennsylvania, and Harvard University. The array includes 21 thin nevi of 
under 1mm, 15 thick nevi of greater than 1mm, 38 radial growth phase primary 
melanomas, 20 vertical growth phase primary melanomas, 28 lymph node metastases and 
45 visceral organ metastases. Thin lesions and metastases had duplicate cores on the 
array. Thick lesions had 3 cores from superficial, mid level and deep parts of the lesion. 
Duplicate cores were taken at each depth for all thick tumors.  
 
Antibody Validation: 
 HMB45: The HMB45 mouse monoclonal IgG (Biogenex, San Ramon California) 
antibody has been used extensively and validated in the Rimm laboratory over several 
years by Bonnie Rothberg and Christopher Moeder.20 They determined that the ideal titer 
of antibody was predilute HMB45 mouse monoclonal IgG (Biogenex, AM001-5M, clone 
HMB45, San Ramon California). A new aliquot of antibody necessitated titering of 
antibodies on YTMA109 test array at predilute, 1:50, 1:100, 1:500, 1:1000, and 1:5000. 




Boutique array. (HMB45 antibody validated by Bonnie Gould-Rothberg and William 
Bradley. Validation on YTMA98-2 by Matthew McRae) 
Nedd9: Nedd 9/HEF1 mouse monoclonal IgG (Abcam, 18056, clone 2G9, 
Burlingame, CA) antibody was used based on previous work in the Rimm laboratory 
suggesting that the ideal concentration for paraffin embedded tissue was at 1:500. 
Immunohistochemically stained melanoma test arrays at 1:50, 1:100, 1:500, 1:1000, 
1:5000 (three orders of magnitude) were analyzed with AQUA. With the ideal titer 
arrived at through analysis of signal to background, the YTMA98-2 Boutique array was 
stained and analyzed with AQUA for cell lines validation. Western blot analysis was then 
executed on cell line lysate to assure that staining was representative of the protein of 
interest. Finally Western blot of cultured human foreskin melanocytes provided by the 
laboratory of Ruth Halaban and cultured by Antonella Bacchiocchi was used to verify 
Nedd9 protein expression in benign melanocytes. This was used as a proxy to verify 
Nedd9 staining in benign nevi.  
The protocol for Western blots was described previously in our laboratory31. The 
primary antibody was Nedd9 (Abcam, 18056, clone 2G9, Burlingame CA) at 1:2000. The 
secondary antibody was goat anti-mouse HRP conjugated (Santa Cruz Biotechnology, 
Santa Cruz CA). The detection system used was SuperSignal West Pico 
chemiluminescent substrate (Thermo Fisher-Pierce Protein Research Products, Rockford 
IL).  (Jason Hanna and Antonella Bacchiocchi grew Cell cultures. Matthew McRae did 





Whole Section Analysis of Typical and Atypical Spitz Nevi, and Spitzoid 
Melanoma: 
  
Dr. Rossitza Lasova and assistant Megan Keenan assembled a cohort of 20 typical Spitz 
nevi, 20 atypical Spitz nevi and 9 Spitzoid melanomas from the recently developed Yale 
Spitzoid neoplasm repository. This is the first repository of human Spitzoid neoplasm’s 
in the world.  Formalin fixed, paraffin embedded samples were cut, mounted on adhesive 
slides and dipped in paraffin for tissue preservation according to standard protocol. Slides 
were stored in nitrogen gas until staining. (Spitz nevi, atypical Spitz nevi and Spitzoid 
melanoma cohort assembled and prepared for staining by Rossitza Lasova and Megan 
Keenan) 
 
Immunohistochemical Fluorescent Staining: 
 Slides were deparaffinized by incubation at 60°C. TMAs were “cooked” for 20 
minutes while whole sections were incubated overnight. This was followed by two 
xylene exchanges. Slides were then rehydrated in sequential washes 100% ethanol, 100% 
ethanol, 70% ethanol and deuterium depleted water. The slides were transferred to 
6.5mM Na-Citrate buffer (pH=6.0) and boiled in a pressure cooker for 10 minutes. An 
absolute methanol with 0.75% hydrogen peroxide solution for 30 minutes was used to 
quench endogenous peroxidase activity of the samples. After a wash in tap water, tris-
buffered saline with tween (TBST) and finally tris-buffered saline (TBS), slides were 
incubated in 0.3% bovine serum albumin (BSA) in TBS for 1 hour at room temperature 




separate slides as the biomarker “target” of interest. Nedd 9/HEF1 mouse monoclonal 
IgG (Abcam, 18056, clone 2G9, Burlingame California) was diluted at 1:500 in BSA 
mixed with TBS. HMB45 mouse monoclonal IgG (Biogenex, AM001-5M, clone 
HMB45, San Ramon California) was manufactured pre-dilute.  
 The “tumor mask” was defined with rabbit polyclonal anti-S100B (DAKO 
Cytomation, Carpenteria, CA) at 1:200 to effectively delineate areas of tumor from 
surrounding tissue and stroma. For TMA slides stained with Nedd9 mouse monoclonal as 
a target only, HMB45 Rabbit monoclonal was added at 1:25 dilution to supplement S100 
tumor mask. The solution containing BSA-TBST with “target” and “tumor mask” 
primary antibodies were aliquoted on each slide and incubated overnight at 4°C. Slides 
were then washed in two exchanges of TBS with Tween detergent and one wash of TBS. 
Envision goat anti-mouse horseradish peroxidase (Dako, Carpenteria California) was 
used as the secondary antibody to the target primary antibody (Nedd9 mouse, HMB45 
mouse). Goat anti-rabbit conjugated Alexa 546nm (Molecular Probes, Eugene Oregon) 
was used a secondary antibody to the tumor mask primary antibody (S100 rabbit, S100 
and HMB45 rabbit on TMA). Goat anti-rabbit Alexa 546 was diluted into the Envision 
mouse (neat) at a ratio of 1:100, aliquoted onto the slides and incubated for 1 hour, at 
room temperature. The fluorescent emission wavelength of the tumor mask was 570 nm.  
 Slides were then washed in TBST followed by TBS alone followed by incubation 
in cyanine-5-conjugated tyramide (Cy5) (Perkin-Elmer, Wellesley Massachusetts) for 10 
minutes to activate the envision mouse horseradish peroxidase for amplified fluorescent 
visualization of the target primary antibody at 670nm (Nedd9 mouse monoclonal IgG 




 Slides were again washed in TBST followed by TBS and then incubated with 4’, 6-
diamidino-2-phenylindole (DAPI) at a dilution of 1:500 in 0.3%BSA-TBST for 20 
minutes. Slides were then washed in TBST followed by TBS. Finally, slides were 
mounted with Prolong® Gold antifade reagent with DAPI (Invitrogen, Carlsbad 
California) and sealed with nylon-based lacquer. DAPI is a fluorescent stain that binds 
strongly to DNA with an emission maximum at 461nm. (Matthew McRae did 
Immunohistochemical staining of TMAs and whole sections). 
  
Digital Image Capture and Automated Quantitative Analysis of Protein 
Expression (AQUA): 
 
 Stained slides were imaged on the HistoRX PM-2000(HistoRX, New Haven, 
Connecticut). This is a modified computer controlled epifluorescent microscope 
illuminated by a high-pressure mercury bulb (Photonic Solution, Mississauga Ontario) 
with a 4 megapixel thermoelectrically cooled monochrome CCD camera.  
 Image Grabber(HistoRX, New Haven, Connecticut) software was used for image 
acquisition of both TMAs and whole sections. The operator (Matthew McRae) first 
acquired a low-resolution image of the slide in the DAPI fluorescence channel. The 
region of sample on the slide was then selected. For TMA analysis, individual spots were 
located automatically with SpotGrabber(HistoRX, New Haven, Connecticut) followed 
by spot verification by the operator (Figure 2). For whole section analysis, the operator 
defined regions of interest manually, and the program then assigned a grid of high power 




high-powered field are as follows: a DAPI channel showing the nucleus in the field of 
focus and 8 microns below the field of focus, a Cy3 channel showing the S100 tumor 
mask in the field of focus and several microns below the field of focus, a Cy5 channel 
showing either Nedd9 or HMB45 in the field of focus and 8 microns below the field of 
focus. A rapid exponential subtraction algorithm (RESA) subtracts the out of focus from 
the in-focus image to dramatically improve the assignment of pixels to a particular 
subcellular compartment (Figure 4).  
 
Figure 2: Low resolution DAPI image taken. SpotGrabberprogram then assigns both a grid 
number and an acquisition order for the HistoRX PM2000 microscope. At bottom right is a nevi at 
20X from YTMA 66A stained with Nedd9 at 1:500 dilution and then further magnified to 





Figure 3: Low-resolution image of the whole section was taken, here of the S100 tumor mask. The 
operator assigns the region of interest by surrounding it with a series of dots connected by a red line. 




Figure 4: S100 defines the tumor mask, DAPI defines the nuclear compartment and subtracting one 
from the other gives the non-nuclear compartment. The target of interest is read in the Cy5 channel. 
In this way compartments can be defined and an AQUA score generated as the intensity of target 
signal per pixel area of a region of interest. An AQUA score can be assigned to the tumor mask, the 
nuclear compartment or the non-nuclear compartment (Adapted from Aaron Berger PhD committee 
meeting presentation32). 
 
 Exposure times were set for S100 tumor mask Cy3 channel at a level where roughly 
25% of brightest spot on TMA or high power field in whole sections was saturated. The 
DAPI and Cy5 target of interest channel underwent auto-exposure controlled by the 
software program. The operator focused the microscope for the first spot (for TMA) or 
high power field (whole section) only as the microscope auto-focused on every spot and 
high-powered field according to the grid assigned prior to high power image acquisition. 
 Cellular compartments were formed by first defining the area of tumor from the 




stained “tumor” or a negatively stained pixel is “not tumor”, in the Cy3, 570nm emission 
channel. Similarly the nuclear compartment (DAPI, 461nm emission) was binary gated as 
pixel that is positively stained and thus “nucleus” versus negatively stained “not 
nucleus.” Only nuclei within the tumor mask were measured. Finally the non-nuclear 
compartment was defined as the area within the tumor mask that was not nucleus.  
 After capturing the images, all TMA spots and high power fields of whole sections 
were reviewed to ensure proper staining. Certain spots and high power fields required 
cropping of the tumor mask and thus removal of that portion of the tumor for analysis. 
The reasons for a region to be cropped were as follows: non-specific staining of S100 
mask such as with lymphocytes that were not in the tumor, folding of the sample on the 
slide resulting in out of focus imaging and altered AQUA scores, and discernable bubbles 
resulting from mounting and cover slipping.  
 With the subcellular compartments defined, quantitative analysis with AQUA® 
software (HistoRX, New Haven, CT) determined the level of fluorescence per pixel area 
on a scale from 0 to 33 000 according to tumor mask, nuclear compartment and non-
nuclear compartment. An AQUA score is defined as the (intensity of target)/(area). The 
AQUA score was further normalized by exposure time and bit depth thus limited to 
signal emanating from the plane of focus. This represented a vast improvement of what 
pathologists commonly rely upon for analysis of IHC, which is generally a numeric score 
from 0 to 4 varying with level of expression subjectively judged by the naked eye. 
(Matthew McRae completed AQUA analysis with the help of Jason Hanna, Elsa 






 TMA spots and whole section high power fields whose mask covered less than 5% 
of the total field area were removed from the analysis. Spots and high power fields 
without adequate compartmentalization as determined by a ratio of nuclear to non-
nuclear DAPI of under 1.5 were also discarded. Exclusion was necessary because despite 
UV cross-linking to the slide, the 0.6 mm histospots sometimes fell off the slide or were 
badly folded or damaged during staining. The reason for poor compartmentalization was 
that the AQUA algorithm was optimized for capture of the entire array and was not 
adjusted for each individual spot. As a result, there were spots that fell outside of the 
optimized range for compartmentalization. 
 Pearson’s correlation coefficient (R) was used to assess the correlation between 
AQUA scores from the same cores on serial cuts of the control array; an R2 greater than 
0.8 was indicative of excellent intra-array reproducibility. 
 For TMA analysis, each tissue spot received an AQUA score according to 
subcellular compartment and tumor mask. To compare the intensity of nuclear to non-
nuclear staining, the natural log of the ratio of nuclear to non-nuclear AQUA scores was 
calculated. This was defined as the “subcellular AQUA ratio.” For whole section 
analysis, a median, mean, maximal and minimal score was taken for each tumor sample. 
The median score was used to compare the natural log of the ratio of nuclear to non-
nuclear AQUA scores.  




lesions was performed by the analysis of variance (ANOVA). Testing for the significance 
of individual pair wise comparisons of each ANOVA was adjusted using the Tukey post 
hoc method for multiple comparisons. Calculation of the receiver-operator characteristic 
curve (ROC) for Spitz neoplasms was performed from the logistic regression model 
measuring the likelihood that a given sample is a benign Spitz Nevus. For all analyses, 
significant associations were defined as p<0.05. All statistical analysis was performed 
using Statview 5.0.1 (SAS Institute Inc., Cary, NC) and SPSS software program (version 
13.0 for Windows, SPSS Inc., Chicago, IL). (Statistical analysis done by Matthew McRae 
and Elsa Anagnostou) 
 
Ethical Use of Human Subjects 
This research protocol involved the use of tissue taken from human subjects as 
well as clinical data related to their diagnosis. This protocol was approved by the Yale 
Human Investigations Committee for the assessment of predictive and prognostic 












Titering on YTMA 109 test array and YTMA 112 resulted in an ideal 
concentration determined for specific staining of NEDD9 antibody at 1:500. This is 
consistent with previous validation done in the Rimm laboratory by William Bradley 
(unpublished results). 
These results were validated on YTMA 98-2 Boutique Array. The boutique array 
contains the MCF-7 cell line. Despite being a breast cancer cell line, it specifically 
expressed cytoplasmic Nedd9 in situ. In addition, all of the melanoma cell lines showed 
specific cytoplasmic staining. A western blot was used to verify the expression of Nedd9 





Figure 5: Western blot of Mel888, a melanoma cell line and MCF7, a breast cell line. Both cell lines 
express Nedd9 protein. Nedd9 is 93kD. 
 
Nedd9 expression in benign nevi showed specific staining with lower level 
AQUA scoring in the tumor mask compared to primary melanoma and showed a 
propensity to the nuclear compartment of the cell. As a proxy for benign nevi, a lysate 
was prepared of cultured human foreskin melanocytes and the Western blot verified 





Figure 6: Western blot of MCF7 cell line lysate and lysate from human foreskin melanocytes. 





The HMB45 antibody had already undergone extensive validation in our 
laboratory 20 however titering of HMB45 on test arrays verified the ideal dilution to be 
the pre-dilute stock solution. It was then stained on YTMA 98-2 cut 60 for validation on 
cell lines prior to experiments using whole sections.   
 
The Subcellular AQUA Ratio for Diagnosing Benign versus Malignant 
Tumor Type 
 





 Beyond the utility of this array for antibody validation and to assess for both inter 
and intra-array reproducibility and specificity of antibody staining, the Yale boutique 
array had a variety of tumor specimens including benign nevi, primary melanoma and 
metastatic melanoma. The distribution of the subcellular AQUA ratio of benign nevi and 
primary melanoma is shown in Figure 7. Unpaired t-test was used to compare the benign 
nevi versus primary melanoma (Figure 8). We demonstrated a clear difference between 
the average subcellular AQUA ratio1 of Nedd9 between benign nevi (mean=-0.429, std 
dev=0.108) and primary melanoma (mean=-0.645, std dev=0.293). 
 
Figure 7: Distribution of median subcellular AQUA ratio for NEDD9 on YTMA 98-2 Cut 53. The 
two tumor types analyzed were benign nevi and primary melanoma. 
 
                                                        
1 Subcellular AQUA ratio = the natural log of the AQUA score in the nuclear 






Figure 8: Boxplot from TMA 98-2 of the subcellular AQUA ratio of nevi versus primary melanoma 
stained with NEDD9 at 1:500. 2 
 
NEDD9: YTMA 66A 
 Regression analysis between cell lines of preparatory YTMA 98-2 boutique cut 
46 and positive control serial section YTMA 98-2 boutique cut 47 stained with YTMA 
66A showed excellent reproducibility with a Pearson correlation coefficient squared (R2) 
between validation and experiment of 0.8241. 
This array was used to verify the staining pattern across a wide variety of benign 
nevi and to directly compare these to metastatic melanoma controls. Figure 9 
                                                        
2 The box of the boxplot itself represents the inter-quartile range (from the 25th to 75th 
percentile) of AQUA scores for all the tumor spots of a specified tumor type. The line in 
the middle of the box is the median score. The t-bars extend to the furthest score that is 
within 1.5 times the inter-quartile range from both ends of the box. Beyond the t-bars, 





demonstrates the staining of Nedd9 in a nevus (a) versus a metastatic melanoma (b). Note 
the heavily cytoplasmic and membranous stain of Nedd9 in the metastatic melanoma 
versus the more nuclear stain of the Nevi. 
 
Figure 9a: Melanoma Metastasis, Nedd9 target  Figure 9b: Benign Nevi, Nedd9 target 
 
The distribution of the subcellular AQUA ratio of benign nevi and primary 
melanoma is shown in Figure 10. Figure 11 is a box plot demonstrating the differential 
expression of Nedd9 in the nuclear to non-nuclear compartment of the cell according to 




inadequate subcellular compartmentalization of the cell as assessed by DAPI staining 
within the cytoplasmic compartment. Of the 40 metastatic melanoma samples, 3 were 
excluded. 
We found that the mean value of the subcellular AQUA ratio was higher for nevi 
(mean=-0.342, std dev=0.159) when compared to the melanoma metastases (mean=-
0.482, std dev=0.149). Unpaired t-test analysis demonstrated a p value of <0.0001. The 
subcellular AQUA ratio for Nedd9 can differentiate benign nevi from metastatic 
melanoma (Figure 11). 
 
Figure 10: Distribution of median subcellular AQUA ratio for NEDD9 on YTMA 66A. The two 






Figure 11: Boxplot showing the subcellular AQUA ratio of benign nevi versus melanoma metastases 
from YTMA 66A nevi array stained with NEDD9 at 1:500.   
 
NEDD9: SPORE 84 Array 
 
 Regression analysis between cell lines of preparatory YTMA 98-2 boutique cut 
44 and positive control serial section YTMA 98-2 boutique cut 45 stained with SPORE 
84 showed excellent reproducibility with an R2 = 0.8622 between validation and 
experiment. 54 of 87 benign nevi, 112 of 136 primary melanoma and 128 of 146 
melanoma metastases originally on the TMA were suitable for scoring (Figure 12).  
The SPORE array was stained with Nedd9 1:500 with differential AQUA scores 
according to tumor type. The distribution of the subcellular AQUA ratio of benign nevi, 
primary melanoma and melanoma metastases are shown in Figure 13. Benign nevi had a 
count of 54 samples with a mean subcellular AQUA ratio of -0.319 (std. dev.= 0.141). 




dev.=0.185) Metastatic melanoma had a final count of 128 with a mean score of -0.42 
(std. dev.=0.188). There was a significant difference between tumor types by ANOVA 
with a p-value of 0.0003 (Figure 14).  
Fisher’s PLSD showed a p-value of 0.0001 between nevi and primary melanoma 
with a p-value of 0.0006 for nevi and melanoma metastases. Tukey/Kramer post hoc 
analysis showed a significant difference between nevi and primary melanoma and 
between benign nevi and melanoma metastasis with significance set at 5%. There was no 
measurable difference between primary melanomas and melanoma metastases. This 
shows in a large independent cohort that the subcellular AQUA ratio is useful in 
differentiating benign nevi from malignant primary and metastatic melanoma lesions. 
 
 
Figure 12: At left is the entire array captured at low resolution on the DAPI fluorescence channel. 
Magnified at 20X is a core from the SPORE 84 array that represents a thick primary melanoma. 
This is further magnified to demonstrate the non-nuclear staining characteristic of primary 






Figure 13: Distribution of median subcellular AQUA ratio for NEDD9 on SPORE 84 array. The 
three tumor types analyzed were benign nevi, primary melanoma and melanoma metastases. 
 
 
Figure 14: Boxplot of NEDD9 staining at 1:500 dilution on SPORE 84 array. The subcellular AQUA 







HMB45: YTMA 98-2 
 
 After titering and validation on test arrays, YTMA 98-2 cut 60 was stained with 
HMB45 predilute primary antibody to verify staining on cell lines and on surgical 
specimens of primary melanoma that could serve as a control for the whole section Spitz 
nevi experiment. 
 The distribution of the subcellular AQUA ratio of benign nevi and primary 
melanoma is shown in Figure 15. The progression from benign nevi (mean=-0.159, std. 
dev.=0.158) to primary melanoma (mean=-0.463, std. dev.=0.264) showed a significant 
difference in the subcellular AQUA ratio. This was significant by unpaired t-test at a 
p=0.0001 (Figure 16). 
 
Figure 15: Distribution of median subcellular AQUA ratio for HMB45 on YTMA 98-2 Cut 60. The 







Figure 16: Boxplot of the subcellular AQUA ratio from YTMA 98-2 of nevi versus primary 
melanoma stained with HMB45.  
 
 
Testing Subcellular AQUA Ratio for Benign vs. Malignant on Spitz 
Nevi, Atypical Spitz Nevi and Spitzoid melanoma 
 
Nedd9 Whole Section Analysis 
 
Regression analysis between cell lines and surgical specimens of preparatory 
YTMA 98-2 boutique cut 52 and positive control serial section YTMA 98-2 boutique cut 
53 stained with whole sections that included whole section analysis of 20 Spitz Nevi, 20 
atypical Spitz Nevi and 9 Spitzoid melanoma, showed good reproducibility of antibody 





The distribution of the median subcellular AQUA ratio of all high power fields 
(20X) per whole section according to tumor type is shown in Figure 17. There is no 
statistically significant difference between the distributions of the scores according to 
tumor type. The mean subcellular AQUA ratio for tumor types were as follows: Spitz 
nevi=-0.169 (std. dev.=0.213), atypical Spitz nevi=-0.036 (std. dev.0.278), Spitzoid 
Melanoma=-0.012 (std. dev.=0.323) (Figure 18). NEDD9 staining of a benign Spitz nevi 
and a Spitzoid melanoma are demonstrated in Figure 19. 
 
Figure 17: Distribution of median subcellular AQUA ratio for NEDD9, 1:500 dilution. The three 






Figure 18: Boxplot of Median value of Nedd9subcellular AQUA ratio. No significant difference was 





        
Figure 19 a is an example of a single high-powered (20X) field of a benign typical Spitz nevi stained 
with NEDD9 and a small region further magnified to appreciate the staining pattern. Figure 19b is 
an example of a single high-powered  (20X) field of a malignant Spitzoid melanoma with a small 
portion further magnified.  
 
 
HMB45 Whole Section Analysis 
 
Regression analysis between cell lines and surgical specimens of preparatory 
YTMA 98-2 boutique cut 60 and positive control serial section YTMA 98-2 boutique cut 
61 stained with whole sections that included 20 Spitz nevi, 20 atypical Spitz nevi and 9 
Spitzoid melanoma, showed excellent reproducibility of antibody staining with a Pearson 




The distribution of the median subcellular AQUA ratio of all high power fields 
(20X) per whole section according to tumor type is shown in Figure 20. There is no 
statistically significant difference between the distributions of the scores according to 
tumor type. The mean subcellular AQUA ratio for tumor types were as follows: Spitz 
nevi= -0.502 (std. dev. 0.316), atypical Spitz nevi= -0.31 (std. dev.=0.26), Spitzoid 
melanoma=-0.535 (std. dev.=0.32)  (Figure 21).  HMB45 staining of a benign Spitz nevi 
and a Spitzoid melanoma are demonstrated in Figure 22. 
        
Figure 20: Distribution of subcellular AQUA ratio for HMB45. The three tumor types analyzed were 






Figure 21: Boxplot of Median value of HMB45 subcellular AQUA ratio. No significant difference was 




        
Figure 22: (a) is an example of a single high-powered (20X) field of a benign atypical Spitz nevi 
stained with HMB45 and a small region further magnified to appreciate the staining pattern. (b) Is 
an example of a single high-powered  (20X) field of a malignant Spitzoid melanoma with a small 
portion further magnified 
 
 
Discovery Analysis: HMB45 Maximum 
 
 The maximum HMB45 AQUA score in the tumor mask (figure 23) for a single 
high power field was able to differentiate between Spitzoid melanoma and both atypical 





Figure 23: The tumor mask on the left defines the area of tumor. The HMB45 Target is then 
measured only if the pixels co-localize where tumor is present.  The maximum total score of a single 
high-powered field was looked at using discovery analysis for the entire cohort. 
 
 Nine Spitzoid melanomas had a mean maximum AQUA score of 825.7 (standard 
deviation 686.6) while the 40 benign Spitz tumors had a mean maximum AQUA score of 




Figure 24: Bivariate scatter gram shows the distribution of maximum AQUA score per whole section 
tissue sample for benign Spitz nevi (both atypical and typical) and melanoma with Spitzoid features. 





 Logistic regression of maximum score of a high power field in a tumor sample 
permitted the construction of a receiver operating characteristic curve. Area under the 
curve can be interpreted as the probability that when we randomly pick Spitzoid 
melanoma and a benign Spitz tumor, the classifier will assign a higher score to the 
Spitzoid melanoma than to the benign Spitz tumor (Figure 25). 
 







Nedd9 and HMB45: Benign nevi, Primary and Metastatic Melanoma on 
Tissue Microarray 
 
Published reports on Nedd9 suggested a role for this protein in melanoma 
metastasis as well showing an increase in tumor expression as tumors progress from 
benign to primary and to metastatic melanoma by IHC25. However, the method of IHC 
was limited to semi-quantitative, subjective, chromogen stained slides. We did a similar 
analysis but instead used fluorescence IHC technique that permitted the automated, 
quantified, reproducible reading of expression levels that can be quantified on a 
continuous scale.  The analysis of expression level of Nedd9 was more carefully 
quantified by the AQUA score within the entire tumor (tumor mask) and the two 
subcellular compartments. The adoption of this technology all but eliminates 
interpretation bias. 
NEDD9 staining on YTMA66A confirmed the published literature of high levels 
of Nedd9 expression in melanoma metastases. By forming a nuclear compartment, the 
“patchy” staining of benign nevi reported was localized predominantly to the nuclear or 
at least peri-nuclear region. This low level expression would likely not be appreciated by 
traditional chromogen staining with hematoxylin counter stain.   
The subcellular localization in our analysis was not perfect. While to the eye, 
expression appeared predominantly nuclear, the absolute levels of Nedd9 expression 




 Despite a small cohort size, YTMA 98-2 allowed for a comparison of Nedd9 
expression between benign nevi and primary melanoma. This quantified and 
substantiated the claim of differential expression by tumor progression and suggested that 
NEDD9 is not only a marker of melanoma metastasis but of progression from a benign to 
a malignant state. The SPORE 84 array was a large independent cohort on which the 
hypothesis of differential expression of subcellular compartments, measured by the 
subcellular AQUA ratio, was powered to view relevant variance in expression by tumor 
type. There was a similar ratio of expression levels in the subcellular compartments in 
both primary and metastatic melanoma. The ratio of expression was significantly 
different however between benign nevi and primary melanoma and between benign nevi 
and metastatic melanoma. The subcellular AQUA ratio score for Nedd9 was valuable for 
distinguishing benign versus malignant, however it was not able to distinguish melanoma 
progression from primary to metastatic.  
Rothberg defined the differential staining pattern by subcellular compartment 
through forming a ratio of the nuclear to non-nuclear compartments and normalizing 
these scores by their natural log. We describe this ratio in this report as the subcellular 
AQUA ratio. HMB45 has been shown conclusively to have the ability to discern between 
benign and malignant by the subcellular localization of IHC using fluorescence 20. In 
validating their data, we noted that while the values between tissue core types remained 
statistically significant, the y-axis was shifted for the benign nevi to a median subcellular 
AQUA ratio of below zero. This observation can be accounted for in two ways. One is 
that the subcellular localization in AQUA 1.6® software (HistoRX, New Haven, CT) can 




of the software, including that done by Rothberg et al permitted optimization for every 
spot. This could account for a more tailored compartmentalization and less leakage of 
nuclear stain being interpreted as “non-nuclear.” This is an inherent difficulty in 
optimizing an automated system. High throughput, reproducible measurements replace 
subjective interpretation of compartmentalization assigned by a technician. The second 
possible explanation for the score shift is that we employed a new AQUA technology that 
uses an algorithm to standardize the AQUA score by exposure time. This was a change 
from the prior experiment as Image Grabber(HistoRX, New Haven, Connecticut) used 
auto-exposure time to optimize exposure times for each histo-spot that was not possible 
with prior editions of the software. While both of these explanations account for the 
variation in AQUA scores between our experiment and that of Rothberg et al. for 
HMB45, it is ultimately not of clinical importance as the difference between benign nevi 
and both primary and metastatic melanoma are maintained.  
NEDD9 and HMB45 reliably differentiated benign nevi from malignant 
melanoma on tissue microarray analysis using the subcellular AQUA ratio. 
 
Whole Section Analysis: Spitz Nevi, Atypical Spitz Nevi, Spitzoid 
Melanoma 
 
Both NEDD9 and HMB45 were chosen for whole section analysis of Spitz lesion 
due to their potential role in melanoma progression. Initial studies completed with both 
biomarkers in our laboratory demonstrated a similar pattern of staining. The benign nevi 
on tissue microarray had nuclear staining while primary and metastatic melanoma had a 




samples were compared and demonstrated that NEDD9 subcellular AQUA ratio had a 
comparable ability as HMB45 to differentiate benign nevi from melanoma. 
Before moving to full section analysis of Spitz tumors, it was first necessary to 
prove differential expression of biomarker expression, in unambiguous terms, between 
benign nevi and malignant melanoma. This was proven in large cohorts using tissue 
microarrays for both HMB45 and NEDD9. While this is novel information that may be 
useful in further analysis of these tumor types, there is very little diagnostic challenge in 
differentiating benign nevi from melanoma using standard methods of pathologic 
evaluation. The real diagnostic dilemma to pathologists lies in the differentiation of 
benign atypical Spitz nevi from malignant melanoma with Spitzoid features.  
 A frequent criticism of TMAs is representation of a heterogeneous tumor. 0.6mm 
cores are only a snap shot of a full section tumor used by pathologists for diagnostic 
evaluation. It has been shown however that whole section and TMA studies have 
excellent levels of concordance particularly with redundancy of 2 or greater cores per 
sample even in heterogeneous tumors such a prostate carcinoma and Hodgkin’s 
lymphoma 28. In addition, TMAs allow for conservation of limited human tumor tissue in 
pathology archives.  
 We moved to whole sections for analysis of Spitz nevi, Atypical Spitz nevi and 
Spitzoid melanoma. There are four reasons for this. First, there is no TMA currently 
available for Spitzoid neoplasms due to their scarcity. Second, there are no concordance 
studies comparing whole section analysis and TMA analysis in Spitz tumors. Third, there 




junctional or dermal component of the tumor, and a tumor core of 0.6 mm could 
theoretically not include all three components. Finally, we wanted to mirror what 
pathologists use in clinical practice. In order to diagnose tumors of melanocytes, 
pathologists use whole sections.  
 Our analysis of Nedd9 and HMB45 on TMAs did not hold up to whole section 
analysis of Spitz tumors. They did not show a differential level of expression according 
subcellular AQUA ratio of benign Spitz nevi, atypical Spitz nevi and Spitzoid melanoma. 
This suggests that these biomarkers, analyzed in this fashion, are not useful in 
differentiating between benign and malignant Spitz tumor types. 
 What did prove of interest on discovery analysis of the cohort was that the 
maximum score of HMB45 of a high-powered (20X) field showed differential expression 
between benign Spitz tumors (typical and atypical) and melanoma with Spitzoid features. 
This would suggest that concentration of gp100 detected by HMB45 in melanoma is 
greater than what is encountered in benign Spitz nevi, whether atypical or typical. A 
focus of very high (quantified by AQUA) HMB45 staining in a Spitz tumor could be of 
important diagnostic utility. This was represented by the associated ROC curve (Figure 
21). While ideally, the ROC would be >0.8 area under the curve, 0.711 is a promising 
area under the curve for a single biomarker in a small cohort. Future analysis on an 
independent cohort is necessary for validation. 
 This analysis is the first set of experiments made possible by the Yale Spitzoid 
Neoplasm Repository organized and managed by Dr. Rossitza Lasova. The repository 




collected from the United States and around the world. Tumor samples are paired with 
relevant clinical data to allow association between histopathologic criteria of the tumor 
and clinico-pathologic features of the patient. The Spitz neoplasm cohort analyzed here is 
particularly valuable as the atypical Spitz nevi and Spitzoid melanoma represent 
equivocal diagnosis. Biomarker profiles that differentiate between benign and malignant 
tumors would therefore be of particular clinical application should they be able to live up 
to this rigorous level of testing.
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